Erin M Massey

US Patent:

20090113564, Apr 30, 2009

Filed:

Mar 28, 2008

Appl. No.:

12/057851

Inventors:

Alejandro Abuin - The Woodlands TX, US
Mark Dominic Borromeo - San Antonio TX, US
Katherin E. Combs - Spring TX, US
Ling Ling Culbertson - Spring TX, US
Zhi-Yong Ding - Longmont CO, US
Joel Edwards - Las Flores CA, US
Liangfen Fan - Spring TX, US
Rosemary Girgis - Houston TX, US
Leslie Jane Green - Conroe TX, US
Allison Anne Byers Horner - Dickinson TX, US
Erin Marie Massey - Conroe TX, US
Dina Rebecca McLain - San Antonio TX, US
Laurie Jeanette Minze - Katy TX, US
Charles Montgomery - Jay OK, US
Bobby Joe Payne - The Woodlands TX, US
Carolina Rangel - Houston TX, US
Arthur T. Sands - The Woodlands TX, US
Tracy Ellen Willis Sevaux - Conroe TX, US
Mary Jean Sparks - Magnolia TX, US
Joy Anne Stala - Dallas TX, US
Peter Vogel - The Woodlands TX, US
Brian Zambrowicz - The Woodlands TX, US

International Classification:

A01K 67/027

US Classification:

800 18

Abstract:

The current invention relates to genetically engineered mice, cells derived from those mice, and polynucleotides and polypeptides corresponding to genes affected by the engineered mutation. The invention also relates to antibodies raised in a mouse of the invention. The invention further provides methods for using the mice, cells, polynucleotides, polypeptides and antibodies of the invention.

US Patent:

20090196876, Aug 6, 2009

Filed:

Oct 18, 2005

Appl. No.:

11/577547

Inventors:

Fred de Sauvage - Foster City CA, US
Dorothy French - San Carlos CA, US
Lino Gonzalez - Menlo Park CA, US
Asja Praetor - Singapore, SG
Weilan Ye - Foster City CA, US
Katherin E. Combs - Spring TX, US
Zhiyong Ding - Longmont CO, US
Allison Anne Byers Horner - Dickinson TX, US
Erin Marie Massey - Conroe TX, US
Charles Montgomery - Jay OK, US
Laurie Jeanette Minze - Katy TX, US
Carolina Rangel - Houston TX, US
Tracy Ellen Willis Sevaux - Conroe TX, US
Mary Jean Sparks - Magnolia TX, US
Joy Anne Stala - The Woodlands TX, US
Peter Vogel - The Woodlands TX, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 39/395
G01N 33/00
C12N 5/10
C07K 16/18
A61P 27/00
A61P 25/00
A61P 25/18
A61P 25/22
A61P 37/00
A61P 13/12
A61P 3/00
A61P 19/00
A61P 9/00
A61P 35/00
A61P 41/00
A61P 3/10

US Classification:

4241581, 800 3, 435325, 435352, 5303871

Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO194, PRO220, PRO241, PRO284, PRO331, PRO354, PRO355, PRO533, PRO541, PRO725, PRO937, PRO1014, PRO1120, PRO1182, PRO1325, PRO1382, PRO1410, PRO1555, PRO1556, PRO1760, PRO1787, PRO1868, PRO4326, PRO4332, PRO4346, PRO4400, PRO6003, PRO6094, PRO6244, PRO9820, PRO9828, PRO10274, PRO16090, PRO19644, PRO21340, PRO92165, PRO85143, PRO1124, PRO1026 or PRO23370 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

US Patent:

20090293137, Nov 26, 2009

Filed:

Nov 16, 2006

Appl. No.:

11/814413

Inventors:

Katherin E. Combs - Spring TX, US
Frederic J. de Sauvage - Foster City CA, US
Liangfen Fan - Spring TX, US
Ellen Filvaroff - San Francisco CA, US
Allison A. B. Horner - Dickinson TX, US
Bryan Irving - San Francisco CA, US
Erin Marie Massey - Conroe TX, US
Dina Rebecca McLain - San Antonio TX, US
Laurie Jeanette Minze - Katy TX, US
Charles Montgomery - Jay OK, US
Bobby Joe Payne - The Woodlands TX, US
Heidi Philips - Palo Alto CA, US
Carolina Rangel - Houston TX, US
Tracy E. W. Sevaux - Conroe TX, US
Mary Jean Sparks - Magnolia TX, US
Joy Anne Stala - Dallas TX, US
Teresa G. Townsend - Houston TX, US
Peter Vogel - The Woodlands TX, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A01K 67/027
C12N 5/06
C07K 16/18
C12Q 1/02
A61K 39/395

US Classification:

800 3, 435325, 435352, 5303879, 435 29, 4241391

Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO218, PRO228, PRO271, PRO273, PRO295, PRO302, PRO305, PRO326, PRO386, PRO655, PRO162, PRO788, PRO792, PRO940, PRO941, PRO1004, PRO1012, PRO 1016, PRO474, PRO5238, PRO1069, PRO1111, PRO1113, PRO1130, PRO1195, PRO1271, PRO1865, PRO1879, PRO3446, PRO3543, PRO4329, PRO4352, PRO5733, PRO9859, PRO9864, PRO9904, PRO9907, PRO10013, PRO90948, PRO28694, PRO16089, PRO19563, PRO19675, PRO20084, PRO21434, PRO50332, PRO38465 or PRO346 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

US Patent:

20090313707, Dec 17, 2009

Filed:

May 18, 2006

Appl. No.:

11/814361

Inventors:

Katherin E. Combs - Spring TX, US
Ling Ling Culbertson - Spring TX, US
Frederic J. de Sauvage - Foster City CA, US
Zhiyong Ding - Longmont CO, US
Joel Edwards - The Woodlands TX, US
Rosemary Girgis - Houston TX, US
Allison A. B. Horner - Dickinson TX, US
Harald Junge - Burlingame CA, US
Jagath Reddy Junutula - Fremont CA, US
Erin Marie Massey - Conroe TX, US
Dina R. McLain - San Antonio TX, US
Charles Montgomery - Jay OK, US
Bobby Joe Payne - The Woodlands TX, US
Heidi Phillips - Palo Alto CA, US
Ni Nancy Qian - San Diego CA, US
Carolina Rangel - Houston TX, US
Tracy E. W. Sevaux - Conroe TX, US
Mary Jean Sparks - Magnolia TX, US
Joy Anne Stala - Dallas TX, US
Peter Vogel - The Woodlands TX, US
Weilan Ye - Foster City CA, US

Assignee:

Genentech, Inc. - South San Francisco CA
Lexicon Pharamaceuticals, Inc. - The Woodlands TX

International Classification:

G01N 33/00
C12N 5/06
C12Q 1/02

US Classification:

800 3, 435325, 435354, 435 29

Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO234, PRO265, PRO309, PRO332, PRO342, PRO356, PRO540, PRO618, PRO944, PRO994, PRO1079, PRO1110, PRO1122, PRO1138, PRO1190, PRO1272, PRO1286, PRO1295, PRO1309, PRO1316, PRO1383, PRO1384, PRO1431, PRO1434, PRO1475, PRO1481, PRO1568, PRO1573, PRO1599, PRO1604, PRO1605, PRO1693, PRO1753, PRO1755, PRO1777, PRO1788, PRO1864, PRO1925, PRO1926, PRO3566, PRO4330, PRO4423, PRO36935, PRO4977, PRO4979, PRO4980, PRO4981, PRO5801, PRO5995, PRO6001, PRO6095, PRO6182, PRO7170, PRO7171, PRO7436, PRO9912, PRO9917, PRO37337, PRO37496, PRO19646, PRO21718, PRO19820, PRO21201, PRO20026, PRO20110, PRO23203 or PRO35250 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

US Patent:

20110097330, Apr 28, 2011

Filed:

Feb 27, 2006

Appl. No.:

11/722967

Inventors:

Allison Anne Byers Horner - Missouri City TX, US
Catherine Batac Clarke - Conroe TX, US
Katherin E. Combs - San Antonio TX, US
Frederic J. de Sauvage - Foster City CA, US
Joel Edwards - Rancho Santa Margarita CA, US
Paul Godowski - Hillsborough CA, US
Deanna Grant Wilson - San Mateo CA, US
Wenhu Huang - San Diego CA, US
Lorelei Diane Ketcherside - The Woodlands TX, US
Erin Marie Massey - Spring TX, US
Charles Montgomery - Jay OK, US
Bobby Joe Payne - The Woodlands TX, US
Andrew Peterson - San Francisco CA, US
Ni Nancy Qian - San Diego CA, US
Jeffrey J. Schrick - Conroe TX, US
Mary Jean Sparks - Corpus Christi TX, US
Joy Anne Stala - Santa Monica CA, US
Colleen M. Viator - Katy TX, US
Peter Vogel - Spring TX, US
Weilan Ye - Foster City CA, US
Jung-Hua Yeh - Belmont CA, US
Zhiyong Ding - Valhalla NY, US

Assignee:

Genentech, Inc. - South San Francisco CA
Lexicon Pharmaceuticals, Inc. - The Woodlands TX

International Classification:

A61K 49/00
C07K 16/18
A61K 39/00
A61P 25/00
A61P 9/00
A61P 37/00
A61P 27/02
A61P 25/24
A61P 25/22
A61P 25/18
A61P 27/06
A61P 27/12
A61P 9/10
A61P 19/02
A61P 19/10
C12Q 1/68
C12N 5/071
C12N 5/0735
C12Q 1/02

US Classification:

4241391, 5303879, 435 6, 800 3, 435325, 435354, 435 29

Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO179, PRO181, PRO244, PRO247, PRO269, PRO293, PRO298, PRO339, PRO341, PRO347, PRO531, PRO537, PRO718, PRO773, PRO860, PRO871, PRO872, PRO813, PRO828, PRO1100, PRO1114, PRO115, PRO1126, PRO1133, PRO1154, PRO1185, PRO1194, PRO1287, PRO1291, PRO1293, PRO1310, PRO1312, PRO1335, PRO1339, PRO2155, PRO1356, PRO1385, PRO1412, PRO1487, PRO1758, PRO1779, PRO1785, PRO1889, PRO90318, PRO3434, PRO3579, PRO4322, PRO4343, PRO4347, PRO4403, PRO4976, PRO260, PRO6014, PRO6027, PRO6181, PRO6714, PRO9922, PRO7179, PRO7476, PRO9824, PRO19814, PRO19836, PRO20088, PRO70789, PRO50298, PRO51592, PRO1757, PRO4421, PRO9903, PRO1106, PRO1411, PRO1486, PRO1565, PRO4399 or PRO4404 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

US Patent:

20110173708, Jul 14, 2011

Filed:

Feb 18, 2011

Appl. No.:

13/031009

Inventors:

Katherin E. Combs - Spring TX, US
Ling Ling Culbertson - Spring TX, US
Juan Delmas-Mata - Spring TX, US
Frederic de Sauvage - Foster City CA, US
Liangfen Fan - Spring TX, US
Gretchen Frantz - San Francisco CA, US
Leslie Jane Green - Conroe TX, US
Erin Marie Massey - Conroe TX, US
Dina Rebecca McLain - San Antonio TX, US
Charles Montgomery - Jay OK, US
Bobby Joe Payne - The Woodlands TX, US
Franklin Peale - San Carlos CA, US
Heidi Phillips - Palo Alto CA, US
Michelle Rohrer - San Carlos CA, US
Tracy Ellen Willis Sevaux - Conroe TX, US
Mary Jean Sparks - Magnolia TX, US
Joy Anne Stala - Dallas TX, US
Tracy Tzu-Ling Tang - Redwood City CA, US
Ching-Yun Wang - The Woodlands TX, US
Wen Xiong - Tomball TX, US
Peter Vogel - The Woodlands TX, US

International Classification:

G01N 33/00

US Classification:

800 3

Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO226, PRO257, PRO268, PRO290, PRO36006, PRO363, PRO365, PRO382, PRO444, PRO705, PRO1071, PRO1125, PRO1134, PRO1155, PRO1281, PRO1343, PRO1379, PRO1380, PRO1387, PRO1419, PRO1433, PRO1474, PRO1550, PRO1571, PRO1572, PRO1759, PRO1904, PRO35193, PRO4341, PRO4348, PRO4369, PRO4381, PRO4407, PRO4425, PRO4985, PRO4989, PRO5737, PRO5800, PRO5993, PRO6017, PRO7174, PRO9744, PRO9821, PRO9852, PRO9873, PRO10196, PRO34778, PRO20233, PRO21956, PRO57290, PRO38465, PRO38683 or PRO85161 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

US Patent:

20110182883, Jul 28, 2011

Filed:

Mar 3, 2011

Appl. No.:

13/040049

Inventors:

Katherin E. Combs - Spring TX, US
Frederic de Sauvage - Foster City CA, US
Liangfen Fan - Spring TX, US
Ellen Filvaroff - San Francisco CA, US
Allison Anne Byers Horner - Dickinson TX, US
Bryan Irving - San Francisco CA, US
Jagath Reddy Junutula - Fremont CA, US
Erin Marie Massey - Conroe TX, US
Dina Rebecca Mclain - San Antonio TX, US
Laurie Jeanette Minze - Katy TX, US
Charles Montgomery - Jay OK, US
Bobby Joe Payne - The Woodlands TX, US
Heidi Phillips - Palo Alto CA, US
Carolina Rangel - Houston TX, US
Tracy Ellen Willis Sevaux - Conroe TX, US
Mary Jean Sparks - Magnolia TX, US
Joy Anne Stala - Dallas TX, US
Teresa Gail Townsend - Houston TX, US
Peter Vogel - The Woodlands TX, US

International Classification:

A61K 39/395
A61P 3/00
A61P 9/00
A61P 25/00
A61P 19/00
G01N 33/00

US Classification:

4241301, 800 3

Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO218, PRO228, PRO271, PRO273, PRO295, PRO302, PRO305, PRO326, PRO386, PRO655, PRO162, PRO788, PRO792, PRO940, PRO941, PRO1004, PRO1012, PRO1016, PRO474, PRO5238, PRO1069, PRO1111, PRO1113, PRO1130, PRO1195, PRO1271, PRO1865, PRO1879, PRO3446, PRO3543, PRO4329, PRO4352, PRO5733, PRO9859, PRO9864, PRO9904, PRO9907, PRO10013, PRO90948, PRO28694, PRO16089, PRO19563, PRO19675, PRO20084, PRO21434, PRO50332, PRO38465 or PRO346 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

US Patent:

20120030776, Feb 2, 2012

Filed:

Oct 22, 2010

Appl. No.:

12/910746

Inventors:

Katherin E. Combs - Spring TX, US
Ling Ling Culbertson - Spring TX, US
Frederic de Sauvage - Foster City CA, US
Zhiyong Ding - Longmont CO, US
Joel Edwards - The Woodlands TX, US
Rosemary Girgis - Houston TX, US
Allison Anne Byers Horner - Dickinson TX, US
Harald Junge - Burlingame CA, US
Jagath Reddy Junutula - Fremont CA, US
Erin Marie Massey - Conroe TX, US
Dina Rebecca McLain - San Antonio TX, US
Charles Montgomery - Jay OK, US
Bobby Joe Payne - The Woodlands TX, US
Heidi Phillips - Palo Alto CA, US
Ni Nancy Qian - San Diego CA, US
Carolina Rangel - Houston TX, US
Tracy Ellen Willis Sevaux - Conroe TX, US
Mary Jean Sparks - Magnolia TX, US
Joy Anne Stala - Dallas TX, US
Peter Vogel - The Woodlands TX, US
Weilan Ye - Foster City CA, US

International Classification:

A61K 49/00
C12Q 1/48
C12Q 1/42
C40B 30/04
C12Q 1/02

US Classification:

800 3, 506 9, 435 29, 435 21, 435 15

Abstract:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO234, PRO265, PRO309, PRO332, PRO342, PRO356, PRO540, PRO618, PRO944, PRO994, PRO1079, PRO1110, PRO1122, PRO1138, PRO1190, PRO1272, PRO1286, PRO1295, PRO1309, PRO1316, PRO1383, PRO1384, PRO1431, PRO1434, PRO1475, PRO1481, PRO1568, PRO1573, PRO1599, PRO1604, PRO1605, PRO1693, PRO1753, PRO1755, PRO1777, PRO1788, PRO1864, PRO1925, PRO1926, PRO3566, PRO4330, PRO4423, PRO36935, PRO4977, PRO4979, PRO4980, PRO4981, PRO5801, PRO5995, PRO6001, PRO6095, PRO6182, PRO7170, PRO7171, PRO7436, PRO9912, PRO9917, PRO37337, PRO37496, PRO19646, PRO21718, PRO19820, PRO21201, PRO20026, PRO20110, PRO23203 or PRO35250 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.